E-MAIL   PASSWORD Forgot password?New user?
Gastroenterology

New Management Strategies for Ulcerative Colitis; DDW – 2007

Optimizing the Use of Biologics to Achieve Goals of Therapy in IBD; DDW-2007

 
The use of biologic agents in the treatment of patients with Crohn’s disease or ulcerative colitis remains a challenge for clinicians. Presently, a number of factors regarding how such therapy can be optimized to achieve goals of therapy remain matters of discussion. For example: Does early intervention with biologics impact the natural history of these diseases? Is it necessary to continue immunosuppressant therapy after biologic therapy has been initiated in order to maintain response? What are the safety issues associated with use of biologic agents and what is their relevance to clinical practice? Is there a pharmacoeconomic advantage to using a biologic agent?

    Pharma Industry / Biotech Industry

    FDA Task Force Seeks Public Comments On Increasing Transparency With Regulated Industry
    Sun, 14 Mar 2010 01:00:00 PDT

    Diabetes

    Diabetes Experts Call For Early, Integrated Treatment Approach To Help Prevent Complications And Improve Patient Outcomes
    Sat, 13 Mar 2010 02:00:00 PDT
    View more >>

    • Irritable bowel syndrome with constipation (IBS-C): Improving primary care assessment and management

      This supplement was submitted by DIME and the Duke University School of Medicine and supported by an independent educational grant from Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc. Irritable bowel syndr...

      Safety of Biologic Therapy

      This educational activity is designed for gastroenterologists and other health care professionals interested in or involved with the management of patients with inflammatory bowel ...

    • Medical Case Views Aligning Biologic Therapy With Disease Severity in Inflammatory Bowel Disease.

      This educational activity is designed for gastroenterologists and other clinicians interested in or involved with the treatment of patients with Crohn's disease and ulcerative coli...

      Chronic Hepatitis C: Treatment Challenges in an Era of Advances: Strategies for Optimizing Current Treatment and the Potential Impact of Emerging Therapies

      Hepatitis C virus (HCV) is the most common chronic blood-borne infection in the U.S. and the leading indication for liver transplantation. Of the estimated 5 million Americans who have been infected, approximately 85% will develop liver disease. In r...

    • Update on Clinical Achievements in Inflammatory Bowel Disease

      The management of patients with inflammatory bowel disease (IBD) remains a challenge for clinicians, as a number of questions regarding the most appropriate clinical course lack definitive answers. For example: How can induction of clinical remission...